Department of Defense Adds Lipogems to Their Arsenal

Premier Medical Technology Available To Order Through DAPA

Musculoskeletal injuries pose the greatest public health problem facing military service members during peacetime and combat. Musculoskeletal issues impact approximately 800,000 service members annually and are the greatest threat to military readiness and the primary reason for medical discharge.

The company Lipogems, is a leading global medical technology company. Today they announced that, through its partnership with Buffalo Supply, Inc., the Lipogems Sports Medicine System is now available within the U.S. Department of Defense (DoD) to help over 2.3 million service members that may be suffering from orthopaedic and wound issues.

Lipogems is a premier FDA-cleared medical technology that uses the patient’s own adipose tissue (fat) and injects it into troubled areas to support the repair and healing of injured or damaged tissue.  The simple, minimally invasive procedure uses only a local anesthetic and can be performed in the clinic, on the field, or added to surgery. For veterans with multiple issues, the fat from one harvest can be used in multiple areas in the same setting. Through the Distribution And Pricing Agreement (DAPA), Lipogems is now available at over 60 hospitals and over 400 clinics, and 2 hospital ships (USNS Mercy, USNS Comfort).

“We are proud and honored to be helping our nation’s brave active military and veterans. Currently, Lipogems is being used by military physicians with great success to help those that have tried conservative options with limited relief for their orthopaedic issues and are not ready for major invasive surgery. DAPA provides better access to the DoD medical facilities and efficient means of supporting the military for their orthopaedic, wound, and burn issues. As a responsible company, Lipogems is supported by strong scientific and clinical evidence with over 70+publications in peer-reviewed journals from leading institutions from around the world. We would like to recognize and thank the Geneva Foundation for the MIRROR Study evaluating Lipogems for knee issues in active military patients and Brooke Army Medical Center for evaluating Lipogems for wound victims. Also, we would like to thank the multiple orthopaedic physicians that have donated the Lipogems procedure to retired Special Operations, veterans, and active military. Our veterans deserve the best access to healthcare and we are proud to help the heroic men and women who serve our country.” Said Carl Llewellyn, CEO, and President of Lipogems USA. Additional information available here.

 

 

 

SourceLipogems

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”